{"release":"wpf-flagship-weight-management","version":"1.4.0","resultsSha256":"7015f8dd771509f9548e11fe120b65641159173a214b88ed02a6a90183b4538e","license":{"name":"Creative Commons Attribution 4.0 International","identifier":"CC-BY-4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"licenseScope":{"covered":["The stable result identifiers (resultId) and the WPF citation strings","WPF's classification of each study's design (kind)","WPF-written estimand summaries (estimand), the analysis-plan section pointers, and the study-specific limitations (limitations)","The field corrections and their basis notes, and the release changelog","The selection, arrangement and structure of the dataset, and its CSV, BibTeX and JSON renderings","WPF-authored verification records (verification): the locator descriptions, verification notes, automated-check descriptions and outcomes, the not-verified lists and WPF's paraphrased summary of the authors' stated limitations","The release metadata and checksum file"],"excluded":["The cited papers and their abstracts, figures and tables (publishers and authors)","Short quotations of third-party text inside verification records (quotedSourceText: registry outcome-measure titles and similar strings). They are marked as third-party","Third-party slide decks and other reproductions linked only as corroboration","ClinicalTrials.gov records, posted results, protocols and statistical analysis plans (linked, not redistributed)","Regulator documents and product labels","Bibliographic identifiers and reported numerical facts as stated by their sources","WPF branding, logos and names","WPF films, transcripts and website copy","WPF repository code"],"unclearAndExcluded":["Fields that closely restate source reports: population, comparator, endpoint, followUp, result, uncertainty, discontinuation, funder and trial names. Ownership of this wording is unresolved, so it is outside the licensed scope until the Owner decides otherwise."]},"suggestedAttribution":"World Peptide Foundation, \"WPF Flagship Weight Management\", version 1.4.0 (2026-11-14), https://www.worldpeptidefoundation.org/releases/wpf-flagship-weight-management/1.4.0/release.json. Licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Please indicate whether you made changes.","result":{"resultId":"surmount-1-weight-72w","candidateId":"tirzepatide:4","kind":"separate_placebo_controlled","trial":"SURMOUNT-1 (phase 3, double-blind)","agents":"Tirzepatide 5, 10 or 15 mg vs placebo","pmid":"35658024","doi":"10.1056/NEJMoa2206038","registryId":"NCT04184622","population":"2,539 adults with BMI 30 or more, or 27 or more with a weight-related complication, excluding diabetes","comparator":"Placebo (1:1:1:1 randomization), including a 20-week dose-escalation period","endpoint":"Percent change in weight and weight reduction of 5% or more (coprimary)","followUp":"72 weeks","result":"-15.0%, -19.5% and -20.9% with 5, 10 and 15 mg vs -3.1% with placebo","uncertainty":"95% CI -15.9 to -14.2, -20.4 to -18.5, -21.8 to -19.9; placebo -4.3 to -1.9","discontinuation":"Treatment-regimen estimand assessed effects regardless of treatment discontinuation, intention-to-treat population.","funder":"Eli Lilly","registryResultsPosted":true,"registryMasking":"Double","estimand":"The abstract states a treatment-regimen estimand (regardless of treatment discontinuation, intention-to-treat). The analysis plan calls the matching estimand \"hybrid\" (regardless of adherence; ANCOVA with multiple imputation, §6.13.1.2). The registry's posted results (-16.0%, -21.4%, -22.5% vs -2.4%) are a different, efficacy-style analysis that excludes data after drug was stopped, so they do not check the displayed values. The plan also says publications would follow the efficacy estimand, and the protocol assigns the efficacy estimand to all purposes other than the FDA submission, which differs from the abstract; this is reported, not resolved.","analysisPlan":{"title":"SURMOUNT-1 Statistical Analysis Plan version 2 (28 Sep 2021), ClinicalTrials.gov NCT04184622","url":"https://cdn.clinicaltrials.gov/large-docs/22/NCT04184622/SAP_001.pdf","sections":"§6.2 General Considerations (estimands); §6.13 Efficacy Analyses; §6.13.1.1 efficacy estimand; §6.13.1.2 hybrid estimand"},"limitations":["Enrolled adults without diabetes; not evidence for people with type 2 diabetes.","The 72-week period included a 20-week dose escalation, so full-dose exposure was shorter than 72 weeks.","Funded by the manufacturer of tirzepatide."],"citation":"SURMOUNT-1 (phase 3, double-blind). Tirzepatide 5, 10 or 15 mg vs placebo. Primary source: https://doi.org/10.1056/NEJMoa2206038 (PMID 35658024; NCT04184622). Cited from World Peptide Foundation, WPF Flagship Weight Management, version 1.4.0, result surmount-1-weight-72w. Versioned record: https://www.worldpeptidefoundation.org/api/research/flagship/weight-management?version=1.4.0&resultId=surmount-1-weight-72w | Result link: https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#surmount-1-weight-72w","releaseVersion":"1.4.0","designLabel":"Separate placebo-controlled trial (not a head-to-head)","designExplanation":"This drug was compared with placebo in its own trial. Setting two trials side by side is an indirect comparison across different populations, durations and designs, so their percentages cannot be subtracted.","verification":{"verifiedOn":"2026-11-12","locators":[{"claim":"-15.0%, -19.5% and -20.9% (5, 10, 15 mg) vs -3.1% (placebo) at week 72, with confidence intervals","source":"PubMed abstract","role":"primary","locator":"Abstract, Results paragraph: reports the week-72 mean percentage change for each tirzepatide dose and placebo with 95% confidence intervals, among 2,539 randomized adults; the Methods sentence names the treatment-regimen estimand, regardless of treatment discontinuation, in the intention-to-treat population.","url":"https://pubmed.ncbi.nlm.nih.gov/35658024/#abstract","status":"matched","method":"scripted","checkId":"pubmed-surmount1"},{"claim":"The same values, printed on a reproduction of the paper's figure","source":"Public reproduction (corroboration only)","role":"corroboration","locator":"ASN Nutrition 2025 conference slides (Gulati), PDF page 22 of 33: reproduces a figure from the NEJM paper. Panel A, whose printed title is overall percent change in body weight from baseline (treatment-regimen estimand), shows -15.0, -19.5 and -20.9 for tirzepatide 5, 10 and 15 mg and -3.1 for placebo. Panel C, with the same estimand label, shows weight-reduction targets.","url":"https://nutrition.org/wp-content/uploads/2025/05/Session-1-2-Gulati-Updated-ASN-Orlando-2025.GULATI.-Patient-Selection-GLP-1RA.pdf","status":"matched","method":"document_read","note":"Corroboration only: a third-party slide, not the paper and not a primary source. WPF read the rendered slide image directly (there is no machine-readable text layer), so this is not scripted. The slide shows no figure number, so the figure number in the original paper is unverified.","quotedSourceText":["Overall Percent Change in Body Weight from Baseline (treatment-regimen estimand)"]},{"claim":"The registry's posted primary result is a different analysis","source":"ClinicalTrials.gov results","role":"primary","locator":"Record NCT04184622, Results tab, primary outcome measure 1 (percent change in body weight, primary treatment period, week 72): posts -16.0 (5 mg), -21.4 (10 mg), -22.5 (15 mg) and -2.4 (placebo).","url":"https://clinicaltrials.gov/study/NCT04184622?tab=results#outcome-measures","status":"different_value","method":"scripted","checkId":"ctgov-surmount1-registry","note":"These are not the displayed values and cannot verify them. The registry's own population description says data after study drug was stopped are excluded, so this is an efficacy-style analysis, while the displayed values come from the paper's treatment-regimen analysis, which includes data regardless of discontinuation. The two analyses answer different questions, so a difference between them is expected.","quotedSourceText":["Percent Change From Baseline in Body Weight (Primary Treatment Period)"]},{"claim":"Which estimand each set of numbers belongs to","source":"Statistical analysis plan","role":"primary","locator":"SAP version 2 (28 Sep 2021): section 6.2 introduces two estimands, efficacy and hybrid; the opening of section 6.13 says which guides which purpose; section 6.13.1.1 specifies the efficacy-estimand analysis (mixed model, efficacy analysis set); section 6.13.1.2 specifies the hybrid-estimand analysis (ANCOVA with multiple imputation, full analysis set, regardless of adherence).","url":"https://cdn.clinicaltrials.gov/large-docs/22/NCT04184622/SAP_001.pdf","status":"matched","method":"document_read","note":"The abstract's treatment-regimen estimand corresponds in content to the plan's hybrid estimand; the plan does not use the label treatment-regimen. The plan also says publications would be guided by the efficacy estimand, and the protocol assigns the efficacy estimand to all purposes other than the FDA submission, yet the abstract headlines the treatment-regimen values. The audit of 2026-11-12 found no accessible primary source that resolves this, so it stays an open question."},{"claim":"Which analysis the protocol assigns to which purpose","source":"Study protocol","role":"primary","locator":"Protocol amendment b (approved 4 Oct 2021), section 9.4.3.1 on primary analyses: defines the efficacy and hybrid estimands; the primary efficacy analysis for the FDA is guided by the hybrid estimand (full analysis set, ANCOVA with multiple imputation) and, for all other purposes, by the efficacy estimand (efficacy analysis set, mixed model). Section 10.1.10 leaves the publication policy to the Clinical Trial Agreement.","url":"https://cdn.clinicaltrials.gov/large-docs/22/NCT04184622/Prot_000.pdf","status":"matched","method":"document_read","note":"Agrees with the analysis plan on the two estimands. The protocol does not mention publications by name; only the analysis plan does. Neither document explains why the paper headlines the treatment-regimen values, which correspond to the hybrid estimand."},{"claim":"Table or figure in the published paper that shows the displayed numbers","source":"Publisher page","role":"primary","locator":"Publisher article page reached through the DOI 10.1056/NEJMoa2206038","url":"https://doi.org/10.1056/NEJMoa2206038","status":"not_read","method":"document_read","note":"An automated request to this address returned HTTP 403 on 2026-11-12, which shows the request was blocked; it does not show why. Europe PMC lists no open-access full text for this paper, and WPF has not established whether the article sits behind a paywall. No table or figure number is claimed."}],"unverified":["The table or figure in the published paper that shows these numbers: not located, because the publisher page could not be read.","The figure number in the original paper for the reproduced panel: unverified.","Whether the paper's body also reports the efficacy-estimand values: not checked, because the publisher page could not be read.","Why the paper headlines the treatment-regimen (hybrid) values although the analysis plan names publications, and the protocol names all purposes other than the FDA submission, as efficacy-estimand uses: unresolved. The best remaining source is the paper's own Methods, which the publisher page did not let WPF read.","The authors' own limitations and disclosure statements: not reviewed, because the full text could not be read."],"automatedChecks":[{"id":"pubmed-surmount1","what":"The abstract reports the displayed values for all three doses and placebo, their confidence intervals, the sample size and the treatment-regimen estimand wording.","method":"Re-runnable script (scripts/verification/verify-weight-management-sources.mts): fetches the PubMed record and compares the extracted abstract with the displayed values.","outcome":"Passed on 2026-11-14","lastRun":"2026-11-14"},{"id":"ctgov-surmount1-registry","what":"The registry's primary outcome measure 1 posts -16.0, -21.4, -22.5 and -2.4, and does not post any of the displayed -15.0, -19.5, -20.9 or -3.1.","method":"Re-runnable script (scripts/verification/verify-weight-management-sources.mts): reads the ClinicalTrials.gov API v2 results record and checks presence and absence of values numerically.","outcome":"Passed on 2026-11-12: the registry reports different values by design (see above)","lastRun":"2026-11-14"}],"humanReview":"none recorded"},"versionedRecordUrl":"https://www.worldpeptidefoundation.org/api/research/flagship/weight-management?version=1.4.0&resultId=surmount-1-weight-72w","analysisPlanUrl":"https://cdn.clinicaltrials.gov/large-docs/22/NCT04184622/SAP_001.pdf","analysisPlanSections":"§6.2 General Considerations (estimands); §6.13 Efficacy Analyses; §6.13.1.1 efficacy estimand; §6.13.1.2 hybrid estimand","registryCheckedOn":"2026-11-11","detailUrl":"https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#surmount-1-weight-72w"}}